AVROBIO (AVRO) Moves On Wells Fargo Initiation. How Much Are Shares Worth?

July 16, 2018 - By Robert Shackelford

Why Has Wells Fargo Given AVROBIO (AVRO) a $40.0 Price Target

Wells Fargo analyst has started coverage on AVROBIO (AVRO) with a $40.0 PT and “Outperform” rating. The PT gives a potential upside of 33.60 % from firm’s last price.

The stock increased 6.55% or $1.84 during the last trading session, reaching $29.94. About 115,555 shares traded. AVROBIO, Inc. (AVRO) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral gene therapies to treat rare diseases following a single dose. The company has market cap of $716.67 million. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. It currently has negative earnings. The Company’s lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease.

More notable recent AVROBIO, Inc. (NASDAQ:AVRO) news were published by: Streetinsider.com which released: “UPDATE: AVROBIO, Inc. (AVRO) IPO Opens 54% Higher” on June 21, 2018, also Nasdaq.com with their article: “Nasdaq’s Hot First Day of Summer – Six IPOs Join our Market” published on June 22, 2018, Seekingalpha.com published: “US IPO Weekly Recap: Biotechs Boom In A 13-Deal Torrent” on June 23, 2018. More interesting news about AVROBIO, Inc. (NASDAQ:AVRO) were released by: Streetinsider.com and their article: “Wells Fargo Starts Avrobio Inc. (AVRO) at Outperform” published on July 16, 2018 as well as 247Wallst.com‘s news article titled: “IPO News This Week: A Record 12 IPOs Coming to Market” with publication date: June 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.